Prime Psychiatry, a leading mental health clinic in Frisco, TX, is now offering Transcranial Magnetic Stimulation (TMS) Therapy as a groundbreaking treatment option for individuals struggling with treatment-resistant depression. TMS Therapy is a non-invasive and non-systemic procedure that utilizes magnetic fields to stimulate nerve cells in the brain, providing a remarkable alternative for patients who have not responded well to previous antidepressant treatments.

Depression can be a debilitating condition, and for those who haven't found relief through traditional treatments, TMS Therapy provides a ray of hope. By precisely targeting specific areas of the brain using magnetic fields, we can stimulate nerve cells and improve the symptoms of depression.

Unlike other treatment options, TMS Therapy can be safely performed in a psychiatrist's office without the need for surgery, anesthesia, or sedation. A typical course of TMS treatment consists of 36 sessions done five days a week over six to nine weeks, with each session lasting for 19 minutes. Patients can easily continue their daily routines before and after each session, making TMS Therapy a convenient and hassle-free option.

At Prime Psychiatry, patients have access to an array of mental health services beyond TMS Therapy. The clinic offers Spravato treatments, medication management, counseling services, substance abuse treatment, and specialized care for child and adolescent mental health.

For more information about TMS Therapy and the services offered at Prime Psychiatry, individuals can visit their website at www.primepsychiatrymd.com. Prime Psychiatry has two convenient office locations in Frisco and Plano, Texas, and their friendly staff is available during office hours to assist with scheduling and inquiries.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

In the ongoing quest to alleviate the burden of depression, a significant breakthrough has emerged in the form of TMS Therapy, now available to patients seeking alternative treatments. TMS, or transcranial magnetic stimulation, offers a non-invasive and non-systemic approach, particularly beneficial for those who haven't found relief with traditional antidepressant treatments. This innovative therapy has gained FDA clearance, marking a pivotal moment in mental health treatment.

Prime Psychiatry stands at the forefront of this advancement, utilizing the cutting-edge Magstim TMS Therapy system. This state-of-the-art device is specifically designed for the TMS procedure, ensuring a high standard of care. Each session under this therapy is concise, lasting only 19 minutes, and is conducted five days a week. A typical treatment course spans 36 sessions, spread over 6 to 9 weeks, allowing for a thorough and effective treatment period.

Beyond TMS Therapy, Prime Psychiatry is committed to offering a comprehensive range of mental health services. Their portfolio includes Spravato Treatments, Medication Management, Counseling Services, Psychiatric Services, Substance Abuse Treatment, and specialized care in Child & Adolescent Mental Health. This diverse array of services ensures that individual needs are met with the utmost care and professionalism.

Accessibility is a key component of Prime Psychiatry's service model. Through telepsychiatry, patients can access these vital services with ease, ensuring that professional help is just a phone call away. The dedicated staff at Prime Psychiatry is readily available during office hours to assist with inquiries, provide information, or schedule appointments, making the journey towards mental wellness as smooth and supportive as possible.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Spravato stands out from traditional antidepressants due to its fast-acting properties. However, it is important to note that Spravato is not recommended for everyone and should only be considered after other conventional treatments have been tried. Prime Psychiatry ensures a thorough psychiatric evaluation to determine if patients are suitable candidates for this cutting-edge treatment.

"We are excited to offer Spravato as a potential game-changer in the treatment of treatment-resistant depression," said Dr. Emily Johnson, a board-certified psychiatrist at Prime Psychiatry. "This medication has shown incredible promise in rapidly improving depressive symptoms and easing the burden on those who have not responded adequately to other treatment options."

Spravato is FDA-approved for specific types of depression and should be used in conjunction with other measures, such as psychotherapy and lifestyle changes. It is important to note that Spravato is not currently approved for the treatment of other mental health conditions.

During the treatment process, patients self-administer the nasal spray under the supervision of the Prime Psychiatry team. To ensure patient safety, individuals are required to stay briefly at the office for monitoring of any potential side effects. As Spravato may affect driving abilities, patients are advised to arrange for alternate transportation to and from the office.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

A new depression medication called Spravato, which has recently undergone clinical trials, is showing great promise at providing relief from symptoms of depression in just a few hours. Symptoms associated with depression can include persistent feelings of sadness, lack of interest in activities once enjoyed, and thoughts of suicide.

Spravato offers new hope for those enduring depression symptoms and offers visible results in treating depression symptoms within just a couple of hours, offering hope and relief for people struggling with depression.

Spravato works by targeting glutamate receptors in the brain, restoring balance, and reducing depressive symptoms. This is the first new depression medication to be introduced in over 30 years. As such, it's expected to be a game-changer for millions of depression sufferers who haven't experienced relief with other traditional treatment methods.

Clinical trials have been conducted to test the effectiveness of Spravato, and the results show that participants experienced relief from depression symptoms in as little as two hours after receiving the medication. This is a significant improvement when compared to traditional treatment methods for depression, which can take weeks or even months to take effect.

Prime Psychiatry considers the potential of Spravato to help our patients manage their depression in a way that works quickly and effectively. Currently, they are recommending this medication for those with treatment-resistant depression, as it has shown great promise in those types of patients.

This breakthrough in depression medication offers renewed hope for those who have given up on finding an effective treatment for their symptoms. With this new option available, they can now experience relief from their symptoms in just a few hours, offering the prospect of a better quality of life.

About Prime Psychiatry

Prime Psychiatry is committed to providing individualized care using evidence-based principles. We provide psychiatric evaluations, medication management, Transcranial Magnetic Stimulation (for treatment of depression), Spravato, telepsychiatry, addiction treatment, disability evaluations and individual/couples counseling. Our services are offered to children, adolescents, and adults from 11–65-years. Prime Psychiatry was founded by Dr Efosa Airuehia, who is quadruple board certified in General Psychiatry, Child and Adolescent Psychiatry, Addiction Medicine and Lifestyle Medicine.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.